AVRO
AVROBIO INC
$1.05
Earnings Summary
Revenue | $0Mn |
Net Profits | $-7.6Mn |
Net Profit Margins | -Inf% |
Highlights
AVROBIO INC’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2017. On a quarterly growth basis, AVROBIO INC has generated NaN% jump in its revenue since last 3-months.
AVROBIO INC’s net profit fell -62.86% since last year same period to $-7.6Mn in the Q4 2017. On a quarterly growth basis, AVROBIO INC has generated -17.93% fall in its net profits since last 3-months.
AVROBIO INC’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2017. On a quarterly growth basis, AVROBIO INC has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the AVROBIO INC post its latest quarter earnings
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Current Year | -0.49 |
Highlights
AVROBIO INC’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a 10.91% jump from last quarter’s estimates.
AVROBIO INC’s earning per share (EPS) estimates for the current year stand at -0.49.
Key Ratios
Key ratios of the AVROBIO INC post its Q4 2022 earnings
Return on Assets (ROA) | -0.43 |
Return on Equity (ROE) | -0.87 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. AVROBIO INC’s return on assets (ROA) stands at -0.43.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. AVROBIO INC’s return on equity (ROE) stands at -0.87.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-11-13 | -0.91 | -0.49 | 46.15% |
2019-03-25 | -0.57 | -0.67 | -17.54% |
2018-08-09 | -0.47 | -2.98 | -534.04% |
2018-03-31 | 0 | -0.5 | -Inf% |
Company Information
AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.
Organisation | AVROBIO INC |
Headquarters | Building 300, Cambridge, MA, United States, 02139 |
Employees | 0 |
Industry | Health Technology |
